Natalizumab (Tysabri) for relapsing multiple sclerosis.
Natalizumab (Tysabri), a selective adhesion molecule inhibitor, decreases the number of relapses and new brain lesions in patients with MS. Administered IV every 4 weeks, it is usually well tolerated, but anaphylaxis can occur and persistent neutralizing antibodies were reported in 6% of patients. No comparisons to other MS treatments and no data concerning its effect on progression of disability are currently available.
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001812:Blood-Brain Barrier / Q000187:drug effects; D002448:Cell Adhesion / Q000187:drug effects; D006801:Humans; D007275:Injections, Intravenous; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D000069442:Natalizumab; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab